Find a Cancer Program  Log in to MyNetwork
Facebook  LinkedIn  Twitter  ACCC Youtube Channel

Search Drug Alphabetically

Generic Name Bexarotene
Brand Name Targretin®
Payment Category Medicare Part D
Year Introduced 1999
Type of Drug Retinoid X receptor activator

FDA-Approved Indication(s)

  • For the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy. (7/29/15)

Approved Indication(s) with Orphan Drug Status Treatment of cutaneous T-cell lymphoma.
ICD-10 Code(s) for Labeled Indication(s) Mature T/NK-cell lymphomas [C84.xx]
Name Strength Form Package Labeler NDC

Copyright © 2021 Association of Community Cancer Centers. All Rights Reserved.
11600 Nebel Street, Suite 201, Rockville, MD 20852  |  Tel.: 301.984.9496  |  Fax: 301.770.1949

CONTACT US